C-CCWDAmbrosia Biosciences
small molecule GPCRs, structural biology, AI molecular design
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CCWD
C-CCWDC-CCWDsmall molecule GPCRs, structural biology, AI molecular design
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Healthcare Weekly Pulse Check Issue #13 March 30 - April 4 Home About us Our Partners Newsletter Subscribe Contact Us More Home About us Our Partners Newsletter Subscribe Contact Us Home About us Our Partners Newsletter Subscribe Contact Us One Stop Platform for early to middle stage businesses One Stop Platform for early to middle stage businesses One Stop Platform for early to middle stage businesses One Stop Platform for early to middle stage businesses Newsletter Subscribe We will publish weekly newsletters of fundraising events. Sign up to hear from us. Email Sign up Social media Weekly N
Colorado BioScience Association and Colorado BioScience Institute Announce New Talent Collaborative - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colorado Industry Impact Capi … skilled workers for the state’s growing life sciences ecosystem. Supported by a grant from the ZOMA Foundation , with facilitation support from SyncUp Colorado , and developed in partnership with Colorado Succeeds , the initiative builds a shared strategy among leading life sciences employers to map talent needs, co-design solutions, and align training and education programs to high-demand roles. This collaborative will use the nationally recognized Talent Pipeline Management … on and Colorado BioScience Institute thank the ZOMA Foundation for the generous grant, creating more opportunities for Coloradans to access mission-driven, high-paying jobs in the state’s life sciences community. About Colorado BioScience Association Colorado BioScience Association (CBSA) creates co-opportunity for the Colorado life sciences community. CBSA champions a collaborative life sciences ecosystem and advocates for a supportive business climate. From concept to comme
Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck | Pennsylvania NY NJ Biotech Networks LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont
Ambrosia Biosciences – Funding, Valuation, Investors, News Dashboard VC firms Startups Pricing News Newsletter About API Terms of Service | © 2019-2026 Parsers, Inc [email protected] Bonus program Sign Up - 10 credits = $1 Terms of Service | ©2024 Parsers, Inc [email protected] --> Add company Sign up Log In Edit Ambrosia Biosciences https://ambrosiabiosciences.com/ Last activity: 01.04.2026 Active Categories: Biotech Cardio GLP-1 Metabolic Pharma Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and o
ambrosia — News — Boulder Ventures Ltd. Who We Are What We've Done News Perspectives Contact Investor Portal Who We Are What We've Done News Perspectives Contact Investor Portal News Posts tagged ambrosia Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline BOULDER, Colo., March 31, 2026 -- Ambrosia Biosciences Inc. (“Ambrosia”) today announced a $100 million oversubscribed Series B financing. The financing provides $100 million in committed capital, intended to fund the Company through
Ambrosia Biosciences | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Ambrosia Biosciences Ambrosia Biosciences Inc. is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. The company aims to deliver safe, effective, and affordable small molecule drugs that transform lives globally, focusing on innovative solutions in the field of metabolic health. Industries biopharma biotechnology health-care Nr. of Employees small (1-50) Ambrosia Biosciences https
Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia All Photos All Videos Business & Money Auto & Transpor … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc. --> -->
%PDF-1.3 %��������� 3 0 obj > stream x�\i� ��^��l����T{5K��IH` �>pH��H�����R�LW�|��iWiy�}���s�y�sy��WS>�����_��Q]5���|���n粟�j��}Y�Q�n ��m[�F,Z�X~��UM�5���݂�\W�Ԕ ο)w� �������+g�hW�^=+���r��?xM��rw��.��C[��0�^�X�C�s��]8�M�����ŎC�F7�6��X�H� � Y� `oEPG5�Fp� g�Ma� �=�gQ�����s5��f��#!��X�c�R.�O����u�� �0���?����������8l�IY���V2�aF�o��̰9QIB����-�! �0����!"1*�y���5�� �� � � '2�c����:����aM���� VV�82w3�h�X�^1���� �T �5�$� MD�ٙyj��$P��T�;D+��A�6�� J8��t,�6��) 5 \�L X��ң�cо�Z�2�/a&r��yɓi.�5�@�.����c�)�6B1�%f��&���/ Q%���@t���c��X�r���� ���!���$
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
John Orwin - Director at Ambrosia Biosciences Inc. | The Org Platform Enrich Pricing Log in Sign up Ambrosia Biosciences Inc. John Orwin Unverified John Orwin Director Contact No bio yet Org chart View org chart 1 View manager View position No direct reports Teams View all teams Leadership 4 people, 0 jobs Offices View all offices This person is not in any offices Related people Alex Stella Fresh Equities Shawn Jones Literacy Resources Grace Harland Spencer Stuart Tyler Berard Canada Goose Jillian Butler ECCO Chris Belfiore Varex Imaging View more Company About Contact Blog Business Solution
John Mayer Discusses Oral Small Molecules for Obesity Treatment | Ambrosia Biosciences Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Ambrosia Biosciences Inc. | The Org Platform Enrich Pricing Log in Sign up Ambrosia Biosciences Inc. 1 follower Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. Industries Biotechnology , Life Sciences Headquarters Boulder, United States Employees 11-50 Links Org chart Teams Offices Positions ( 31 ) Unverified Org chart Nick Traggis President / COO 18 Nick Traggis Collapse David Snitman Director 0 Jason Haddock Director 0 John Orwin Director 0 William Marshall Director 0
Ambrosia Biosciences Raises $100M for GLP-1 Pipeline | cGxP.wire posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
David Snitman - Director at Ambrosia Biosciences Inc. | The Org Platform Enrich Pricing Log in Sign up Ambrosia Biosciences Inc. David Snitman Unverified David Snitman Director Contact No bio yet Org chart View org chart 1 View manager View position No direct reports Teams View all teams Leadership 4 people, 0 jobs Offices View all offices This person is not in any offices Related people Alex Stella Fresh Equities Shawn Jones Literacy Resources Grace Harland Spencer Stuart Tyler Berard Canada Goose Jillian Butler ECCO Chris Belfiore Varex Imaging View more Company About Contact Blog Business
David S. Snitman - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile David S. Snitman Founder and Director at Ambrosia Biosciences Inc. David S. Snitman 's Executive Work History Current Founder and Director , Founder and Director Equilar on 03/28/2026 Ambrosia Biosciences Inc. Past To view David S. Snitman's complete e
Richard Shoemaker - Google Scholar Loading... The system can't perform the operation now. Try again later. Citations per year Duplicate citations The following articles are merged in Scholar. Their combined citations are counted only for the first article. Merged citations This "Cited by" count includes citations to the following articles in Scholar. The ones marked * may be different from the article in the profile. Add co-authors Co-authors Follow New articles by this author New citations to this author New articles related to this author's research Email address for updates Done Sor
%PDF-1.7 %���� 1 0 obj >/Metadata 72 0 R/ViewerPreferences 73 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 21 0 R 22 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]Ko$�� ��m`z�&�F3��p��`�0�=y�8� H_Mv���LI6 �4�C��U�� >|�����Ç O? ~{ ��}��>���� ��������`� '=|� ��� �� ���\������������/�wg�o�w����0�rR��ЃjT�@O�~r-�X���^I��� �$�k327�I��.�y���V3�.��ӑO���� �ubG|��O&��_�ǃ�W��gz���#x=�G&|����Q�p��W/R3��5R�c�����KU�k�ʓ>rS��d�T>������|aJ� |���90 ���
Biocaptiva Raises £1.58M in Funding Led by ARCHANGELS | Startup Rise Europe News posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … isting shareholders, including the company’s founders and the Demcon Innovation Fund. Joost De Bruijn | Frank-Jan van der Velden | Erik Vossenaar | Wietse Mulder . 🔗 Read full article link in comment #CellTherapy #Biotech #StemCells #ATMP #Innovation #MedTech #Biomanufacturing #Utrecht #Investment #HealthTech #StartupFunding #CAR_T #iPSC #Osilaris #news 98 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Startup Researcher Europe 5,265
%PDF-1.7 %���� 1 0 obj >/Metadata 102 0 R/ViewerPreferences 103 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 35 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][� �q~��0���xi6�a�3# �A $Y~0�X� y�&���#M6/UEVO��9֒�F6Y��W_O �� =}�����?}>������N���������������?�ߩA��-ڜ�iZ��/���������_߿�|}���>i}����wz��:铝e�ɏn����������������_|�;��?N_����/�����w�/��Nx�Zt�F/�>M� �"a��\�I��(����@dLC-�6&#IT�i� � ?�JNU��`QT�"�a�����1S�����L+������l Y ���ɅK���9_���O�"����l
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.3 %��������� 5 0 obj > stream xŜˎ Ǖ���� �K��H@���F-�YX�h� g k1�?��QU��Y�H X ��k_4��� �tb�m+�� \�SD��h� �).д�OW ��[��Hb1*�� E�` |��g��_���^�ɭ(g!6U@���XT�lrr�$Bl�+Q�c�� �W^*�u��N��a$�vn�� + �*�;E*�۾�},������[�LU�L���� ������W ������a��!� �b�r��v��l=��響�R;��IAs&��p�zeXvJ��+3�ϒ H�i��"JQE�����ӄ������Mi&J)-K9n�d-���� �;�Q� ��Y������t��h��p��3J�J��ȧ�.v@wN�ظ�� 46W����D=0�%�G�~�R�FI� �O��w�X@6�;9f��3�x����`���x��� ��D�S��fj!x�N*!��7%d�Mj^�]o��X �S({��(��}ybԟ�� � p� _6(a�OT=8g� �d�Ȩm�,���� J,�e�_X��J-)SZ�ߘ(lfA;�'M���> ?wU,UKy�~�Y�Dͅ9FWU~�M��� … �z�-JR%�K����J��! w ��;d��. ��패���v� �y����38ybH�b�ጇ�����C�a�+�2V�O�㏖RFp� G|��emB��K�J;E����x��둑��b(� �WH���l���.=s�ҁ��-�ɧ�IQN�#8G'>����@���=�"����i�Osץ#��v�3��� �� ��Z���m�����D6�T���zj|?x�����u�B�oP� �~^O���h�&O����G���A� [�Oz�=�[� Ƣ# �Q�A���,�/�S��G42� �=s��h��/ �"� ��?����pJ���B������ �O��$~� |A�����8#��`��������P��2 �?�ڇ�ua �osl�˴$���G �>z����S��RQ#��1���q@ ��s�ƭu4Z�Y$�Σ�s 1A�����=��/4�jz�6R�[��a� ~��m�m��mC��R
Cure’s Biotech Funding Tracker 2026 Contact us News & Insights Cure Innovation Index Healthcare News Investment Founder Stories Cure Original Reports Cure Conversations Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard June 22, 2026 What Makes an Institution Innovative? A Cure Original Report April 29, 2026 Apply for Membership Work in NYC Join Now Cure Residents People of Cure Your Home in NYC Members can access hotdesking, private conference rooms, event space, a cafe, and a gym—all within a healthcare focused environment. Learn More Learn More Attend An Event Attend … youthful function in old cells without altering DNA Notable Investors: Founders Fund (lead); Thrive Capital, Greenoaks, Quiet Capital (new); Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital (existing) NewLimit closed a $435M Series C led by Founders Fund to push its first cell-aging reprogramming therapy into human trials in 2027. Its lead program is designed to speed liver healing after injury, blunt the effec … cipating) Cambridge, Mass.-based CREATE Medicines raised $122M in a Series B to fund its push into in vivo CAR therapies for autoimmune disease and cancer. The company uses an mRNA-LNP platform to reprogram T cells, NK cells, and myeloid cells directly inside the body, an approach that has been tested in more than 50 patients to date. The new funding will advance lead autoimmune candidate CRT-402, a CD19-targeted therapy designed to be redosed, along with a dual CD19 x BCMA p … ital LLC (co-leads, both existing); Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, Pangaea Ventures, FemHealth Ventures, Triple Impact Capital, Uncommon Denominator (participating) Princeton, N.J.-based Kanvas Biosciences r aised a $48M Series A to fund clinical trials of KAN-001, its lead immuno-oncology live biotherapeutic for patients who do not respond to immune checkpoint inhibitors. The financing brings total funding to $78M and also supports commercial partnerships … CE) antibody platform Notable Investors: GL Ventures (lead); a sovereign wealth fund (new); existing shareholders Redwood City, Calif.- and Shenzhen, China-based LTZ Therapeutics closed an oversubscribed $38M financing to advance its U-MCE platform, bringing total funding to roughly $130M since the company's founding in 2022. Proceeds will s
Annual Awards Celebration - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colorado Industry Impact Capital + Growth Grants Startups CBSA > Annual Awards Celebration Annual Aw … ax Selected as Rising Star Finalists; Enveda Honored with 2025 Deal of the Year Award Denver – Colorado BioScience Association (CBSA) announces the finalists for its prestigious annual awards, recognizing the companies and leaders driving health innovation across Colorado’s thriving life sciences ecosystem. Hundreds of life sciences leaders will gather for an evening of impact, inspiration, and connection at the 22nd Annual Awards Celebration Presented … Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors. Enliven Therapeutics | Boulder Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but … world from preventable disease. Earlier this year, the company announced a new grant of up to $5M from the Coalition for Epidemic Preparedness Innovations (CEPI), enabling VitriVax to leverage its Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology for a single-dose rabies vaccine. Deal of the Year Sponsored by BioMed Realty During the high-profile celebration, CBSA will also honor Colorado’s Deal of the Year, Enveda ’s rise from Seed to Series D in fi … ce in Manufacturing Sponsored by Brownstein The new Excellence in Manufacturing Award honors a company advancing the science of life-saving medicines. Educator of the Year Sponsored by Fisher Scientific Honors an outstanding educator shaping the future of Colorado’s life sciences workforce. Institute Leadership Sponsored by Biod
Welcome to Ambrosia Biosciences Andrea Flynn, Ph.D.! Andrea joins Ambrosia Biosciences Inc. as Chief Business Officer. Andrea has consistently leveraged her extensive investor relations… | Ambrosia Biosciences Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at
G2GBIO Partnership Advances Semaglutide Research | Samsung Bioepis posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Efforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colorado Ind
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Ambrosia Biosciences | pharmaphorum Skip to main content Thursday 25 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Development Market Access Oncology A
Ambrosia Biosciences Advances Small-Molecule GLP-1 Agonists with $100M Series B Funding | BioIntel BioIntel ABOUT SUBSCRIBE AI IN DRUG DISCOVERY BIOPHARMACEUTICAL INDUSTRY BIOTECH INNOVATION HEALTHCARE INVESTMENT MEDICAL TECHNOLOGY REGULATORY & POLICY Biotech Innovation Ambrosia Biosciences Advances Small-Molecule GLP-1 Agonists with $100M Series B Funding Biotech Innovation Ambrosia Biosciences Advances Small-Molecule GLP-1 Agonists with $100M Series B Funding Dr. Alex Morgan • Apr 1, 2026 • 10 min In a significant development within the treatment of metabolic diseases, Ambrosia Bioscienc
Ambrosia Biosciences Raises $100M for Obesity Therapies | AI Tech Supports posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … llowers 2mo Report this post 💰 Paris-based JEITO Capital has closed its second fund at $1.2 billion (above €1 billion), making it the largest raise ever by a fully independent European #biopharma fund. Jeito II will invest in 15 to 20 clinical-stage biopharma companies with average investments of up to €150 million per company. The women’s health relevance: Jeito has already deployed capital into reproductive medicine, backing ReproNovo in a $65 million round in May 2025. 🤝 … al #lifesciences #europe European Biopharma Investor Jeito Capital Closes $1.2B Fund https://femtechinsider.com 14 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 9,479 followers View Profile Follow More from this author Alta Ares Raises €50M to Become a Leading European Player in Air Defense AI Tech Supports 1w OpenAI launches AI-powered personal finance experience in ChatGPT for U.S. Pro users AI Tech Supports 1mo Caracol’s Vision for Autonomou
FDA's Upcoming Review on Cancer Treatments and Industry Shifts in Biotech and Pharma Products Data Feature Plans Request Demo Sign Up for Free FDA's Upcoming Review on Cancer Treatments and Industry Shifts in Biotech and Pharma 30 August 2024 The Food and Drug Administration (FDA) is set to convene a panel of expert advisers on September 26 to evaluate the use of Bristol Myers Squibb ’s Opdivo and Merck & Co. ’s Keytruda in the treatment of gastrointestinal cancer . The advisory committee will focus on assessing PD-L1 expression as a predictive biomarker for the effectiveness of t
#jpm2026 #biotech #pharma #healthcare | Ambrosia Biosciences Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Pri
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-o … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
S-1 1 d53570ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2026. Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 First Tracks Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 39-5003207 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial … improvement; (iv) “BLA” refers to a Biologics License Application, a formal request submitted through the FDA seeking approval to market a biological product in the United States; (v) “CDAI” refers to a validated rheumatoid arthritis disease-activity score based solely on clinical assessment. It is calculated using a linear sum of the 28-joint tender joint count, the 28-joint swollen joint count, the patient’s global a … tion; (xvii) “IND” refers to investigational new drug application to the FDA; (xviii) “Proof-of-concept” refers to early-stage, small studies that focus on initial efficacy, mechanism of action, pharmacokinetics (PK), and preliminary safety in a limited patient group to determine if the concept is viable and warrants further development; (xix) “PROs” or “Patient-Reported Outcomes” refers … lacement On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (“EcoR1”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Selling Stockholders” and each, a “Selling Stockholder”), pursuant to which, following the closing of the Spin-Off, First Tracks Biotherapeutics issued and sold an aggregate 5,791,479 shares of … plans, we believe that our existing cash, cash equivalents and investments will fund our current operating plan beyond the next 12 months. In connection with the Private Placement, we entered into a registration rights agreement with the Selling Stockholders (the “Registration Rights Agreement”) at the closing of the Private Placement
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Healthcare Private Placement and M&A Transactions Review Week Ending August 25, 2024 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending Aug … 7;s pre-money valuation at $41.5 million. Touchdown Ventures, Colorcon, iSelect Fund, Alumni Ventures, Sage Hill Investors, Claridge Venture Partners, Keen Growth Capital and GenHenn Capital also participated in the round. The company is a developer of clinical nutritional and wellness products. Ambrosia Biosciences: The company raised $16 million of Series A venture funding in a deal led by Boulder Ventures, BVF Partners, and other undisclosed investors on August 20, 2024, p
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Ambrosia Biosciences: Funding, Team & Investors | Startup Intros Home / Organizations / Ambr
Ambrosia Biosciences Raises $100M for Next-Gen GLP-1 Therapies | Vincent Zucconi posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … in The Sontag Foundation 1,974 followers 2mo Report this post Sontag Innovation Fund portfolio company, TippingPoint Biosciences, recently announced the closing of an oversubscribed $4.5M seed round to advance their mission of unlocking new therapeutic strategies for some of the most devastating diseases, starting with DIPG. Read more: https://bwnews.pr/4dk6bLN 26 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Wilson Sonsini Goodrich & Rosat … ation from Catalyst Investments and investors including the Florida Opportunity Fund . https://lnkd.in/dvzyYxgb Omeza Raises $8.5M in Series A Funding https://www.finsmes.com 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Shari Hulitt 2mo Report this post What if the science isn’t the problem? Last week at Business of Biotech in Tampa ( BioFlorida, Inc. ), one theme kept coming up in different ways: there’s no shortage of innovation, but there
| Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Description A clinical-stage biopharmaceutical company focused on "immune reset" therapeutics for chronic immune-mediated diseases using T-cell engagers. Website: Ouro Medicines Business Area(s) T-Cells Immunotherapy Autoimmunity Company Location(s) 701 Gateway Blvd, Unit 410 South San Francisco , CA 94080 Uni
Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia All Photos All Videos Business & Money Auto & Transportat … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc. --> -->
%PDF-1.7 %���� 9 0 obj > stream x��]ێ�}����ъwX,0=;c�!@.��plAl$���CJ�Dv�HUݚ���v��YQ�X�s�H6R��ϡ����Z4A�������m�� y��6�9H�U� �֡ ��_����?�/d���Y�{��\N�qH��͡�� >|�?���*�"h�E*���Y�^��/ _ >�����?>��s|������Ç}��&t�{�!ӵT ���� �;����m��tx��C�V��u|�� @�|�Tc�UB�� �%�Ʃ6h�/�2|�������@�BeX�U.�6.%ۢp����MN_Q�\�� � �_O�_�w������~�}� �e� H��@�/ֺ� �ߵ��穰�� �����?++W�+/�۵>���~����� ��S~]�٢�E�]����g#vv�8�kt5 ��am�3H0�� \�2�9O�ә�#3 �Ԏ �C'�P��1�8O��s�2�P���rV�m�[o7F��рÈ� G� W}�Ǚ� 4N��1�p&��Q���� �2�bA���[3,? g)څ�GOy�\� `B�4U L�,I�� O�?��S�χEJG�kT~n�����������y�w�O … Ðg U۶\AE�z tڧj�� ���c���n�÷��I�w�����^� � ��c�7��~J.S^��:x:�B�6n� �� ؏e�^�rfP�o�� p! �pN_�:ߴ|����6kha��U�$��Ց+:|�G�a\�ʶ{��AM� 1t��,���Wz���� #��Iӆ`/5��v��>�}ю/����A�L��Y-~ӥ[d��|�[ C���B� ��q �}b��Gr�\�tr��J�2�]i�sY�3Q��}N#�Z+� ��jM��#M�ݲ ���m�9[(����!���ں �����YO�eX�\� '&en�4Q X�W��K���/���ů� D�ay �ք~��o9 n��Ta3�ݴ)6HM�f8�b���͍�o��M Ѧ�`���҉Im��^h��U��*���iƒ�З��%`k�|j�s�0��*�OS����7���;B����]�.D[æ�A��hXe�͂�WdL�p�4�8� � ~�Oƣ��x
Colorado BioScience Association Announces Finalists to be Honored 21st Annual Awards Celebration, Presented by AGC Biologics - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colo … by Good Growth Capital with participation from RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund, AOA Dx relocated to Colorado in 2024. Since moving to Denver, the company has continued to gain recognition for its groundbreaking work in research publications and national news outlets, including BMJ Oncolo … tech companies, PhotonPharma closed a $2.5M seed round in 2024, secured a state grant, and received clearance from the U.S. Food & Drug Administration for a first in human clinical study for Stage III/IV ovarian cancer treatment. Ambrosia Biosciences, Inc. – Ambrosia is scaling its drug discovery programs and laboratory operations in Boulder, reuniting a team of medicinal chemistry experts specializing in small molecule drug discovery from Array Biopharma, which wa … e Year Sponsored by Fisher Scientific, Colorado BioScience Institute Leadership Award, Volunteer of the Year, Legislators of the Year, Business Partner of the Year, Building Momentum Award Sponsored by BioMed Realty, and the Lifetime Achievement Award. Keynote Speaker Brooke Eby CBSA welcomes ALS advocate Brooke Eby as the keynote speaker for this year’s event. Diagnosed with ALS at age 33, Brooke has used her platform to challenge misconceptions about the disease and raise a
#skin #research | LEO Foundation // LEO Fondet LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and C … n across 105 grants - a 40% increase in grants year-on-year. With the launch of Grant Strategy 2030, we aim to significantly strengthen global #skin #research and accelerate progress toward curing skin diseases. ⚖️ A resilient and diversified portfolio delivering solid performance, supporting the Foundation’s long-term financial strength. Together, these results reflect our continued commitment to improving the lives of people living with skin diseases - and to bringing new t … n across 105 grants - a 40% increase in grants year-on-year. With the launch of Grant Strategy 2030, we aim to significantly strengthen global #skin #research and accelerate progress toward curing skin diseases. ⚖️ A resilient and diversified portfolio delivering solid performance, supporting the Foundation’s long-term financial strength. Together, these results reflect our continued commitment to improving the lives of people living with skin diseases - and to bringing new t
Structure Therapeutics Inc._December 31, 2025 http://xbrl.sec.gov/country/2025#US http://xbrl.sec.gov/country/2025#US 0001888886 FY http://xbrl.sec.gov/stpr/2025#CA http://xbrl.sec.gov/stpr/2025#CA http://xbrl.sec.gov/stpr/2025#CA P2Y http://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember 0.0001 http://xbrl.sec.gov/country/2025#US http://fasb.org/us-gaap/2025#RelatedPartyMember http://structuretx.com/20251231#SchrodingerInc.Member false 0001888886 gpcr:ExpenseOfResearchAndExperimentalExpenditureMember 2025-01-01 2025-12-31 0001888886 gpcr:CapitalizationOfResearchAndExp … eding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes ☒ No ☐ ​ ​ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” … xisting cash, cash equivalents and short-term investments will be sufficient to fund our future operating expenses and capital expenditure requirements; ● our expected use of net proceeds from our financing transactions; ● the impact of laws and regulations; ● the impact of geopolitical and macroeconomic factors; and 3 Table of Contents ● other risks and uncertainties, including those described under Part I. Item 1A. “Risk Factors” in this … n, we have never conducted later-stage clinical studies or submitted a New Drug Application (“NDA”), and may be unable to do so for any of our product candidates. ◾ The marketing approval processes of the U.S. Food and Drug Administration (“FDA”) and applicable foreign authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our busine … PK”) and pharmacodynamic (“PD”) activity. We submitted an IND application to the FDA to support initiation of a Phase 1b study in T2DM and obesity and received FDA allowance in September 2022. We initiated the Phase 1b multiple ascending dose (“MAD”) study of aleniglipron in January 2023 and completed dosing in other
Ambrosia Biosciences - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors &
All Biotechnology News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ove … ication, enabling the... Apr 15, 2026, 23:32 ET Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical... Apr 15, 2026, 20:00 ET Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab) Mabwell (688062.SH), an innovative bioph … tive ... Apr 15, 2026, 09:15 ET Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ... Apr 15, 2026, 09:10 ET Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships Lunai Bioworks, Inc. (NASDAQ: LNAI) ("L … ET Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announces the submission of a supplemental Biologics License... Apr 14, 2026, 16:29 ET Zweites internationales Symposium … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 9 --> 9 10 --> 10 11 --> 11 12 --> 12 13 --> 13 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is select
Ambrosia Biosciences Raises $25M in Series A Financing | This Week in Digital Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U … Evan Rachlin , MD, and Lorence Kim , MD, has closed its inaugural $325 million fund to invest in development-stage biotechnology companies. The fund’s backers include institutional investors, family offices, endowments, and high-net-worth individuals. Ascenta focuses on early clinical-stage biotechs developing multi-medicine therapeutic platforms and has already deployed over $100 million across six companies, including ADARx Pharmaceuticals, Iambic Therapeutics, Odyssey The … apeutics, Odyssey Therapeutics, Cardurion Pharma, OrsoBio, and Alpha9 Oncology. FUND NAME: Fund I AMOUNT: $325,000,000 HQ: #WestPalmBeach #Florida #VentureCapital #AscentaCapital #EvanRachlin #LorenceKim #TradedVC 1 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Chris Lehman 8mo Report this post October 16-20, 2025 headlines: Viridian’s $300 Million Royalty Financing Alto’s $50 Million Private Placement, Valink’s $12 Million Pre-A, Tow … Million Private Placement, Valink’s $12 Million Pre-A, Town Hall’s $440 Million Fund Raise, Veradermics’ Oversubscribed $150M Series C, C4’s $125 Million Public Offering, Adcytherix’s $122 Million Series A, Peptilogics’ $78 Million Series B2, Conexeu’s $5 Million Fund Raise, from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Viridian Therapeutics, Inc. Alto Neuroscience Valink The … up to $35 million, together with a $5 million share purchase plan, primarily to fund the next stage of clinical trials of its innovative radiopharmaceutical products for cancer diagnosis and treatment. The placement attracted strong investor interest and included a strategic $7.6M investment by NASDAQ-listed Lantheus Holdings, Inc. supporting Rad
Z Biotech Celebrates 10 years of Innovation and Partnership at Fitzsimons Innovation Community. - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colorado Industry Impact Capital
Ambrosia Biosciences launches with $16 million from investors - Daily Camera DRUG DISCOVERY Ambrosia Biosciences launches with $16 million from investors By Lucas High BizWest / Prairie Mountain Media Ambrosia Biosciences Inc., a recently formed drug-discovery company, has raised a $16 million Series A round and reunited a team of scientists that previously worked for Pfizer Inc.’s (NYSE: PFE) now-shuttered Boulder research and development operation. The funding round for Ambrosia, which will initially focus on developing small-molecule drug therapies for obesity and … Boulder, we have re-assembled the Array medicinal chemistry team at Ambrosia to apply that same expertise to obesity.” The company will focus its early efforts to “discover and develop novel orally delivered, small molecule-based therapies targeting incretins and other class B GPCRs (a type of secretin receptors regulated by peptide hormones),” Ambrosia said. Ambrosia was founded by Nick Traggis, who was previously the CEO of LightDeck Diagnostics, a medical-test maker acquir
Colorado-Real-Estate-Journal_437197 1 9 11 72 Colorado-Real-Estate-Journal_437197 Page 10 - January 1-14, 2025 www.crej.com Industrial by Avalon Jacka DENVER – A 695,899-square- foot logistics center in the Northfield submarket sold in October for the first time since completion. FC Stapleton Industrial LLC sold the two-building Central Park Logistics Center, located at 9300 and 9400 E. 46th Place, to Third Avenue Invest LLC for $100.1 million, according to SKLD Information Services. The seller entity is affiliated with project developer Brook- field Properties. The buyer entity’s address is a … d round of Series A financing, totaling $25 million, in December. Local biotech fund Boulder Ventures Biotech Fund, San Francisco-based hedge fund BVF Partners and global pharmaceutical com- pany Merck backed the most recent round of funding. The company also closed a found- ers’ seed round in March and its first Series A funding round in July. The new facility is Ambrosia Bioscience’s first official loca- tion; the company used the offices of local investors since the compan … rming Ambrosia Biosciences was the ability to recruit the former Array team and apply the small molecule develop- ment expertise of Array to the company’s new obesity targets. “When Pfizer shut down the Array site, that’s a team that is near and dear to us,” Traggis said. “Many of us came from Array or have worked with teams from Array before. One of our lead investors, Boulder Ventures, was actually one of the founding investors of Array BioPharma as well. [The facility gave
Invest In Ambrosia Biosciences Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Ambrosia Biosciences Stock Invest in or calculate the value of your shares in Ambrosia Biosciences or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Ambrosia Biosciences Stock Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. Invest Now Sell Shares About Ambro … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
Ambrosia's sweet $100m round, and other biofinancings | pharmaphorum Skip to main content Thursday 25 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & … e, UK-based Immutrin completed a Series A, raising £65 million ($87 million) to fund the development of its antibody-based therapy for ATTR cardiomyopathy, a serious and often fatal form of amyloidosis, through to proof-of-concept. The drug binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response, according to the company. The round was led by Frazier Life Sciences with participation from F-Prime, Qiming V … MDD that recently had positive results in a phase 2 trial. The new funding will fund further development of that drug and also support the start of phase 1 trials of an ibogaine analogue, κ-opioid receptor (KOR) agonist GM-3009, with potential as a treatment for opioid use disorder. The Series A financing was led by Satori Neuro, alongside participation from new and existing institutional investors, including Prime Movers Lab. Image by Mohamed Hassan from Pixabay Image Phil T … llowed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo. Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry. Deep Dive Why pharma needs honest patient dialogue Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug
AlloSource Strives to Advance Healing - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose Colorado Industry Impact Capital + Growth Grants Startups CBSA > AlloSource Strives to A … orld Economic Forum recently selected Humacyte as a 2017 Technology Pioneer, an award designated for organizations that are poised to have a significant impact on business and society. “We are growing blood vessels currently used in clinical trials for hemodialysis,” said Cycyota. “That’s incredible. Work taking place here in Colorado has the potential to impact patients around the world.” Since its inception, AlloSource has been a part of the Colorado bioscience community. T
Colorado Biotech Ambrosia Biosciences Secures $100M in Funding | Kyle LaHucik posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
This past Monday I defended my PhD from University of Wisconsin–Madison! I want to give a huge thank you to Tehshik Yoon and the Yoon group for their help and support over the years. An additional… | Cade MacAllister | 26 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update
%PDF-1.7 %���� 1 0 obj >/Metadata 818 0 R/ViewerPreferences 819 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 1920 1080] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��S]k�0}7�?�G�`���_��� ���=�>(��j�sԇ��ZJH���Ȋ�%_]�{��qtٛf�J����=��ȥdX�f}�{��@�^4[�Po|�A�Og�c�W����~� \�!����h~u;����t�̞E�%��2ۮ.f���Q���V�U��:��N�@+u��r�N��w � ��r�c`L"�\ ӊi&�[!E� >0�SgE �yeT�c��C�xQzHDߔ�!�t�sAƅ �cR �o��b ��^�� d.�!�2E�������-f����A_�I@Ҁ�1> > endobj 6 0 obj > stream ����JFIF``���E
Ambrosia Biosciences Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
Ambrosia Biosciences Inc. | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Ambrosia Biosciences Inc. Ambrosia Biosciences Inc. Private Boulder, Colorado Healthcare & Life Sciences https://ambrosiabiosciences.com Last Round Series B Mar 31, 2026 Total Funding Raised $141M Company Overview Ambrosia Biosciences Inc. is a biotechnology company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. Sector Health … ss Model B2B Customer Profile Services & Consulting, Revenue Share AI Layer Application Keywords oral GLP-1 small molecule drugs obesity drugs drug discovery platform AI drug discovery structure-based drug discovery weight loss drugs G-protein coupled receptors GPCRs GLP-1 receptor agonist metabolic disorders drug licensing Class B GPCRs cryo-EM preclinical biotech Historical Pricing Historical view of private secondary pricing and transaction trends. Unlock Pricing Chart
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Colorado BioScience Association Honors 2025 Life Sciences Leaders at 22nd Annual Awards Celebration, Presented by AGC Biologics - Colorado Bioscience Association Networking + Events Policy + Advocacy Member Center Career Center Choose Colorado JOIN CBSA Meet CBSA News + Blog Institute Login Search Site Networking + Events Calendar Drive to Five: Life Sciences Innovation Tour Annual Awards Celebration Investor & Partnering Conference Policy + Advocacy Policy Priorities Take Action Member Center Member Benefits Member Success Sponsorship Member Directory Member Portal Career Center Choose C … ciences Recognized as Rising Star of the Year, Enveda Receives Deal of the Year Award Denver, Colorado – November 14, 2025 – Colorado BioScience Association (CBSA) announced the winners of its 22nd Annual Awards Celebration, presented by AGC Biologics, recognizing the people and organizations advancing Colorado’s position as a leading hub for health innovation. The awards spotlight leaders whose work accelerates breakthrough discoveries and delivers impact for patients in Col … ce of Economic Development and International Trade. The Rising Star of the Year award went to Ambrosia Biosciences , a Colorado-founded company formed when a world-class team of medicinal chemists from Pfizer and Array Biopharma were reunited under the leadership of CEO Nick Traggis and Kyle Lefkoff of Boulder Ventures. Powered by leaders with deep Array BioPharma experience, Ambrosia is targeting metabolic disorders that affect millions of patients. The company came out of s … s. The company came out of stealth with a $16 million Series A round led by BVF Fund and Boulder Ventures, later expanded to $25 million with an investment from Merck, and is advancing its small-molecule programs from the former Array and Pfizer campus. CBSA also congratulates Rising Star of the Year finalists EnteroTrack , RheumaGen , and VitriVax . Enveda received the Deal of the Year Award, sponsored by BioMed Realty , for a landmark financing year that underscored Colorad … to improving and saving lives. Additional Honorees Excellence in Manufacturing Award, Sponsored by Brownstein: Agilent Technologies Agilent Technologies has chosen Colorado for growth for more than sixty years, with facilities in Boulder and Frederick. In Frederick, Agilent manufactures therapeutic nucleic acids for genetic and RNA-based therapi
Ambrosia Biosciences bags $100m for obesity drugs BioXconomy is part of the Informa Connect Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. About Events Advertise Stay Updated Stay Updated Partnering Related Topics Licensing M&A Growth Strategy Recent in Partnering See All Partnering ‘I'd like it to be our secret’: Why pharma execs are
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Ambrosia Biosciences | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Ambrosia Biosciences Website: Ambrosia Biosciences Business Area(s) Small Molecules GPCR (G Protein Coupled Receptor) Artificial Intelligence Description Ambrosia Biosciences is developing orally delivered, small-molecule therapies for obesity and metabolic disorders. Led by former Array B
Ambrosia Biosciences Inc. - Leadership | The Org Platform Enrich Pricing Log in Sign up Ambrosia Biosciences Inc. Teams Leadership Unverified Leadership 4 people · 0 jobs This department focuses on strategic oversight and decision-making to guide the organization. People ( 0 ) No people in this team Jobs ( 0 ) No jobs in this team Other teams View all teams Medicinal Chemistry 4 people · 0 jobs Finance and Operations 3 people · 0 jobs Research Science 3 people · 0 jobs Drug Metabolism Department 2 people · 0 jobs Legal Affairs 2 people · 0 jobs Company About Contact Blog Business Solutions T
Senior / Principal Scientist, DMPK - Ambrosia Biosciences Inc | BeBee Skip to main content Jobs People Services Resume Builder Blog United States Jobs School Principal Senior / Principal Scientist, DMPK Back Senior / Principal Scientist, DMPK Marketing Ambrosia Biosciences Inc Boulder , United States $110,000 - $125,000 /year 2 weeks ago Until 8/12/2026 Apply Adapt my CV to this job Job description About the job Senior / Principal Scientist, DMPK Senior / Principal Scientist, DMPK Department: Research & Development Location: Boulder, CO (onsite) At Ambrosia Biosciences, our mission is to d … n and candidate selection. Deep understanding of ADME/DMPK principles and their application to multiparameter optimization in drug discovery, specifically covering metabolic stability, permeability, protein binding, solubility, metabolite profiling, and drug‐drug interaction risk. Experience working effectively in cross‐functional discovery teams and translating complex data into actionable scientific recommendations. Additional Skills Experience with human PK prediction, PK/ … e employment eligibility of all newly hired employees. Interested in this role? Apply Adapt my CV to this job Connecting talent with opportunities. Jobs, services, and freelance in one place. Navigation Search jobs People Companies Services Talent Salary Guide Job Market Report Industries Job Market by City Skills Professions Job Market Trends Remote Jobs Blog Employer resources BeBee For job seekers For employers Offer your services Find a professional Bloggers About How It
Ambrosia Biosciences Our Science Pipeline Team Investors News Careers Contact Our Science Pipeline Team Investors News Careers Contact Ambrosia Biosciences Enduring Health, Designed from the Molecule Up Get in touch News Ambrosia Announces Preclinical Data Supporting Differentiated Profile of AMB-702 About Us Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. Our scientific team brings deep expertise across every stage of structure-based drug discovery, with contributions to 30 IND filings, 25 … received numerous awards, including the 2009 Outstanding Scientific Achievement Award from the American Diabetes Association. Kieran Chacko, PhD Strategic Advisor Kieran Chacko, PhD Strategic Advisor Kieran Chacko is Executive Vice President of Data Science and Corporate Strategy at Harbinger Health and a co-founder and Advisory Board member of Ambrosia Biosciences. He brings deep experience in biotechnology venture creation, company building, and corporate strategy. As a fou … lso have a beer named after us.) Senior / Principal Scientist, DMPK Boulder, CO Apply Now Ambrosia Biosciences is an equal opportunity employer, and we are committed to a work environment free of discrimination, harassment and retaliation. Employment opportunity is based on an individual’s capabilities, experience and qualifications, without regard to protected characteristics established by law. Latest on LinkedIn Follow us Contact Us General Inquiries [email protected] I
Ambrosia Biosciences Inc. Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Sign In Free Trial Sign In Free Trial Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Ambrosia Biosciences Inc. https://ambrosiabiosciences.com/ Industry Biotechnology Pharmaceuticals See more in Biomedtracker Latest on Ambrosia Biosciences Inc. Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker Twitter feed RSS feed RSS feed Podcast Spotify About About Us Opens in new window Meet the Team Editorial St … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window Publications Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Terms and Conditions Opens in new window Privacy Policy Opens in new window
Ambrosia Biosciences | | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene The … with Lilly 24 June 2026 Biotechnology Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies 24 June 2026 Biotechnology 105M upfront for Antares in Novartis deal 24 June 2026 Biotechnology EC backs Padcev-Keytruda combination before and after surgery in bladder cancer 24 June 2026 Biotechnology Combotope Thera enters collaboration with Boehringer 24 June 2026 Biotechnology Osanni Bio raises $190 million Series B to advance therapeutics platform 24 J
Ambrosia Biosciences launches with former Array BioPharma chemists --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section How biochemistry fuels World Cup athletes Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House Australia’s $1.4 billion PFAS lawsuit could be a global model The road to sustainable rare earth … data sets near the end of 2025 and then file its first investigational new drug application with the US Food and Drug Administration around the end of 2026. Ambrosia will use the new cash to establish operations in Boulder, where the team is already working. “At this stage, what I’m most proud of is that we were able to take bad news for the local community and its shutdown of this R&D site and find a place for a good chunk of that staff to land on their feet and be part … Braner covers the life sciences from New York City. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Advertisement Enjoyed the article? Share Ambrosia Biosciences launches with former Array BioPharma chemists The GLP-1 focused firm starts with a $16 million series A cen.acs.org Advertisement More in Start-ups Editor's Picks Popular Return to top 2/3 FREE ARTICLES
Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mu … inancing. The financing provides $100 million in committed capital, intended to fund the Company through clinical trial initiation of its oral small molecule GLP-1 . The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor. … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Ambrosia Biosciences announces $16MM Series A Financing Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia All Photos All Videos Business & Money Auto & Transportation Aerospace, Defense Air Freight Air … oulder , we have re-assembled the Array medicinal chemistry team at Ambrosia to apply that same expertise to obesity." While this is a very active space, there is significant science yet to be understood and plenty of opportunity to improve upon existing GLP-1 based drugs. I'm proud of the work our founding science team has already done and look forward to using this financing to scale up our drug discovery efforts. Post this The Company will initially discover and develop no … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc. --> -->
Illinois Biomanufacturing Receives $1.5B Investment | John Conrad posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … 𝐧𝐜𝐥𝐮𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 We’re delighted to welcome Cinclus Pharma to the Claret Fund IV portfolio. Cinclus Pharma is a late-stage clinical pharma company developing next-generation treatments for gastric acid-related diseases. 🔹Cinclus Pharma’s lead asset, linaprazan glurate, has potential to relieve symptoms of gastroesophageal reflux disease more effectively than current treatments, affecting around 133m adults in the US and EU 🔹Claret is proud to support another late-sta
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Antiaging Drug Development Roadblocks and FDA Favored Approaches | Jennifer Smith-Parker posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Ambrosia Biosciences Announces Late-Breaking Poster Presentation at the American Diabetes Association's (ADA) 86th Scientific Session - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Ambrosia Biosciences Announces Late-Breaking Poster Presentation at the American Diabetes Association’s (ADA) 86th Scientific Session April 21, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Poster presentation will feature the preclinical profile of Ambrosia's novel oral small molecule GLP-1 rec … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Business Takeda enters transitional year as new CEO seeks return to growth June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities an … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B April 1, 2026 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, volody10 While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a smal … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate June 7, 2026 | 3 min read Twitter LinkedIn Facebook Email Print AMB-702 demonstrates superior target coverage and efficacy in lean non-human p … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline March 31, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Proceeds will support advancement of the Company's oral small molecule GLP-1 candidate and other novel ca … inancing. The financing provides $100 million in committed capital, intended to fund the Company through clinical trial initiation of its oral small molecule GLP-1 . The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin